Lecozotan Explained

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients.^[1], the first Phase III clinical trial has been completed.^[2]

Method of action

Lecozotan is a competitive, selective 5-HT_1A receptor antagonist^[3] which enhances the potassium-stimulated release of acetylcholine and glutamate.^[4]

Notes and References

1. Spreitzer H . August 13, 2008 . Neue Wirkstoffe - Lecozotan . Österreichische Apothekerzeitung . 17/2007 . 805 . German .
2. http://clinicaltrials.gov/ct2/results?intr=%22Lecozotan+SR%22 ClinicalTrials
3. Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers W . 6 . Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties . The Journal of Pharmacology and Experimental Therapeutics . 314 . 3 . 1274–89 . September 2005 . 15951399 . 10.1124/jpet.105.086363 . 1506.05421 . 16444551 .
4. Childers Jr WE, Harrison, BL, Abou-Gharbia, MA, Raje, S, Parks, V, Pangalos, MN, Schechter, LE . Lecozotan Hydrochloride . Drugs of the Future . 2007 . 32 . 5 . 399–407 . 10.1358/dof.2007.032.05.1092901 .